The research training grant GRK2504 at the Friedrich-Alexander-Universität (FAU) was approved by the committees of the Deutsche Forschungsgemeinschaft (DFG) in May 2019. Accordingly, our training and research programme will begin in October 2019. We are now starting to recruit doctoral candidates in sciences that will pursue their research projects in Erlangen. In autumn 2019, recruitment procedures will be continued for doctoral candidates in medicine, for clinician scientists, for associated training members, and for young researchers that were trained at FAU and wish to perform their research projects with one of our collaboration partners at the Ragon Institute of MGH, MIT and Harvard.
Our training programme in Erlangen offers structured curricula for doctorates in science and medicine and for clinician scientists pursuing an academic career. All measures intend to support profound scientific training and to familiarise with translational research.
Our research programme aims to explore novel approaches for antiviral chemotherapy and immune intervention that build upon recent developments in molecular virology and immunology. The individual research projects address antiviral small molecules (area A), immune cell-mediated antiviral effects (area B), and antibody-based approaches (area C). Altogether, we envision multimodal antiviral strategies that combine antiviral chemotherapy with immune-based interventions as the most promising path towards the control of persistent viruses.